Site icon OncologyTube

Common Questions Asked Regarding c-Met in RCC

Aly-Khan Lalani, MD of Dana-Farber Cancer Institute summarizes the common questions colleagues ask him concerning his study on c-Met expression in renal cell carcinoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 4573: Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression

Advertisement
Exit mobile version